Show simple item record

dc.contributor.authorPlans-Rubio, Pedro
dc.contributor.authorNavas, Encarna
dc.contributor.authorGodoy, Pere
dc.contributor.authorCarmona, Gloria
dc.contributor.authorDomínguez, Ángela
dc.contributor.authorJané, Mireia
dc.contributor.authorMuñoz-Almagro, Carmen
dc.contributor.authorBrotons, Pedro
dc.date.accessioned2021-02-11T18:34:02Z
dc.date.available2021-02-11T18:34:02Z
dc.date.issued2019
dc.identifier.citationPlans-Rubio, Pedro; Navas, Encarna; Godoy, Pere [et al.]. Reduction of direct health costs associated with pertussis vaccination with acellular vaccines in children aged 0–9 years with pertussis in Catalonia (Spain). PharmacoEconomics - Open, 2019, 3, p. 55-69. Disponible en: <https://link.springer.com/article/10.1007%2Fs41669-018-0081-4>. Fecha de acceso: 11 feb. 2021. DOI: 10.1007/s41669-018-0081-4.ca
dc.identifier.issn2509-4262ca
dc.identifier.urihttp://hdl.handle.net/20.500.12328/1986
dc.description.abstractObjectives: The aim of this study was to assess direct health costs in children with pertussis aged 0–9 years who were vaccinated, partially vaccinated, and unvaccinated during childhood, and to assess the association between pertussis costs and pertussis vaccination in Catalonia (Spain) in 2012–2013. Methods: Direct healthcare costs included pertussis treatment, pertussis detection, and preventive chemotherapy of contacts. Pertussis patients were considered vaccinated when they had received 4–5 doses, and unvaccinated or partially vaccinated when they had received 0–3 doses of vaccine. The Chi square test and the odds ratios were used to compare percentages and the t test was used to compare mean pertussis costs in different groups, considering a p < 0.05 as statistically significant. The correlation between pertussis costs and study variables was assessed using the Spearman’s ρ, with a p < 0.05 as statistically significant. Multiple linear regression analysis (IBM-SPSS program) was used to quantify the association of pertussis vaccination and other study variables with pertussis costs. Results: Vaccinated children with pertussis aged 0–9 years had significantly lower odds ratios of hospitalizations (OR 0.02, p < 0.001), laboratory confirmation (OR 0.21, p < 0.001), and severe disease (OR 0.02, p < 0.001) than unvaccinated or partially vaccinated children with pertussis of the same age. Mean direct healthcare costs were significantly lower (p < 0.001) in vaccinated patients (€190.6) than in unvaccinated patients (€3550.8), partially vaccinated patients (€1116.9), and unvaccinated/partially vaccinated patients (€2330). Multivariable linear regression analysis showed that pertussis vaccination with 4–5 doses was associated with a non-significant reduction of pertussis costs of €107.9 per case after taking into account the effect of other study variables, and €200 per case after taking into account pertussis severity. Conclusions: Direct healthcare costs were lower in children with pertussis aged 0–9 years vaccinated with 4–5 doses of acellular vaccines than in unvaccinated or partially vaccinated children with pertussis of the same age.ca
dc.format.extent15ca
dc.language.isoengca
dc.publisherSpringer Natureca
dc.relation.ispartofPharmacoEconomics - Openca
dc.relation.ispartofseries3;
dc.rightsThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.ca
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subject.otherVacunesca
dc.subject.otherTos ferina
dc.subject.otherInfants -- Salut i higiene
dc.subject.otherVacunas
dc.subject.otherTosferina
dc.subject.otherNiños -- Salud e higiene
dc.subject.otherVaccines
dc.subject.otherPertussis
dc.subject.otherChildren -- Health and hygiene
dc.titleReduction of direct health costs associated with pertussis vaccination with acellular vaccines in children aged 0–9 years with pertussis in Catalonia (Spain)ca
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc61ca
dc.identifier.doihttps://dx.doi.org/10.1007/s41669-018-0081-4ca


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc/4.0/
Share on TwitterShare on LinkedinShare on FacebookShare on TelegramShare on WhatsappPrint